CA2218555A1 - Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs - Google Patents

Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs

Info

Publication number
CA2218555A1
CA2218555A1 CA002218555A CA2218555A CA2218555A1 CA 2218555 A1 CA2218555 A1 CA 2218555A1 CA 002218555 A CA002218555 A CA 002218555A CA 2218555 A CA2218555 A CA 2218555A CA 2218555 A1 CA2218555 A1 CA 2218555A1
Authority
CA
Canada
Prior art keywords
compositions
nonsteroidal antiinflammatory
methods
antiinflammatory drugs
toxicity induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002218555A
Other languages
French (fr)
Other versions
CA2218555C (en
Inventor
David S. Garvey
L. Gordon Letts
H. Burt Renfroe
Sang W. Tam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Nitromed, Inc.
David S. Garvey
L. Gordon Letts
H. Burt Renfroe
Sang W. Tam
Nicox S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/425,090 external-priority patent/US6051588A/en
Application filed by Nitromed, Inc., David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Sang W. Tam, Nicox S.A. filed Critical Nitromed, Inc.
Publication of CA2218555A1 publication Critical patent/CA2218555A1/en
Application granted granted Critical
Publication of CA2218555C publication Critical patent/CA2218555C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C203/00—Esters of nitric or nitrous acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/28—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising: (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed.
The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs.
CA002218555A 1995-04-19 1996-04-11 Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs Expired - Fee Related CA2218555C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/425,090 1995-04-19
US08/425,090 US6051588A (en) 1995-04-19 1995-04-19 Nitroso esters of β-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US08/543,208 US5703073A (en) 1995-04-19 1995-10-13 Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US08/543,208 1995-10-13
PCT/US1996/004931 WO1996032946A1 (en) 1995-04-19 1996-04-11 Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs

Publications (2)

Publication Number Publication Date
CA2218555A1 true CA2218555A1 (en) 1996-10-24
CA2218555C CA2218555C (en) 2003-09-23

Family

ID=27026571

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002218555A Expired - Fee Related CA2218555C (en) 1995-04-19 1996-04-11 Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs

Country Status (6)

Country Link
US (11) US5703073A (en)
EP (1) EP0821589B1 (en)
JP (2) JPH11509519A (en)
AU (1) AU710951B2 (en)
CA (1) CA2218555C (en)
WO (1) WO1996032946A1 (en)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US6043232A (en) * 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
AU737584B2 (en) * 1995-04-19 2001-08-23 Nicox S.A. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
IT1282686B1 (en) 1996-02-26 1998-03-31 Nicox Sa COMPOUNDS ABLE TO REDUCE DRUG TOXICITY
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
IT1288123B1 (en) * 1996-09-04 1998-09-10 Nicox Sa USE OF NITRO-DERIVATIVES FOR URINARY INCONTINENCE
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
WO1999007363A1 (en) * 1997-08-08 1999-02-18 Medosan, Ricerca S.R.L. Use of the compound 2-methoxyphenyl-1-methyl-5p-methylbenzoyl-pyrrol-2-acetamido acetate for the production of an anti-inflammatory drug with prevention of gastric hypersecretion and renal impairment
US6656452B1 (en) * 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
US6136327A (en) * 1997-12-01 2000-10-24 Alza Corporation Stereospecific delivery of a drug using electrotransport
GB9801398D0 (en) 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
US6121249A (en) * 1998-07-01 2000-09-19 Donald L. Weissman Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins
EP0984012A3 (en) * 1998-08-31 2001-01-10 Pfizer Products Inc. Nitric oxide releasing oxindole prodrugs with analgesic and anti-inflammatory properties
EP1126838A4 (en) * 1998-10-30 2005-02-16 Nitromed Inc Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
EP1140066A4 (en) * 1998-11-17 2005-11-09 Nitromed Inc Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
AU781133B2 (en) * 1999-02-26 2005-05-05 Nicox S.A. Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6605115B1 (en) * 1999-06-05 2003-08-12 Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
IT1313596B1 (en) * 1999-08-04 2002-09-09 Nicox Sa PROCESS FOR THE PREPARATION OF NITROXIALKYL ESTERS OF NAPROXENE
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
US6552078B2 (en) 1999-10-27 2003-04-22 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
TWI262791B (en) 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US7105172B1 (en) * 1999-11-18 2006-09-12 Bolla John D Treatment of rosacea
BR0017037A (en) * 1999-12-23 2003-06-10 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
CA2396165C (en) * 2000-01-14 2011-01-04 John F. Hunt Airway alkalinization as therapy for airway diseases
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US8519005B2 (en) 2000-07-27 2013-08-27 Thomas N. Thomas Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy
US6417347B1 (en) 2000-08-24 2002-07-09 Scimed Life Systems, Inc. High yield S-nitrosylation process
TWI249519B (en) 2000-08-29 2006-02-21 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
WO2002060378A2 (en) * 2000-12-21 2002-08-08 Nitromed, Inc. Substituted aryl compounds as cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP1219306A1 (en) 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
EP1406608B1 (en) 2001-05-02 2009-07-29 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
EP1399161B1 (en) * 2001-06-05 2011-04-20 Control Delivery Systems Sustained-release analgesic compounds
ITMI20011744A1 (en) * 2001-08-09 2003-02-09 Nicox Sa DRUGS FOR VASCULOPATHIES
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030162824A1 (en) * 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
US6627602B2 (en) * 2001-11-13 2003-09-30 Duke University Preventing desensitization of receptors
US20040110691A1 (en) * 2001-11-13 2004-06-10 Stamler Jonathan S. Thiol reactive agents as a therapeutic modality
WO2003043657A1 (en) * 2001-11-19 2003-05-30 Control Delivery Systems, Inc. Topical delivery of codrugs
JP4771659B2 (en) * 2001-11-27 2011-09-14 ニコックス・ソシエテ・アノニム New method
ES2189682B1 (en) * 2001-12-11 2004-04-01 Laboratorios Del Dr. Esteve, S.A. DRINKABLE PREPARATION UNDERSTANDING KETOPROPHEN AND ITS EMPLOYMENT IN THE PROCESSING OF PROCESSES PROCESSING WITH FEVER, INFLAMMATION AND / OR PAIN, IN AN ANIMAL COLLECTIVE, SIMULTANEOUSLY.
AU2003223491A1 (en) * 2002-04-05 2003-10-27 Nitromed, Inc. Nitric oxide donors, compositions and methods of use
JP2005533013A (en) 2002-04-19 2005-11-04 イスム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティ オブ エルサレム Beta agonist compounds containing a nitric oxide donor group and a reactive oxygen species scavenging group, and use of the compounds in the treatment of respiratory disorders
AU2003229016A1 (en) * 2002-05-10 2003-11-11 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagatingvaricella zoster virus and methods of use thereof
JP2006501161A (en) * 2002-06-11 2006-01-12 ニトロメッド インク． Nitrosated and / or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
US20040038947A1 (en) * 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
JP2005535642A (en) * 2002-06-28 2005-11-24 ニトロメッド インコーポレーティッド Nitrosated and / or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use containing oximes and / or hydrazones
CA2491127A1 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
CA2493156A1 (en) * 2002-07-29 2004-02-05 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP1534278A4 (en) * 2002-08-01 2006-09-06 Nitromed Inc Nitrosated proton pump inhibitors, compositions and methods of use
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
DE10248601B4 (en) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmaceutical agent for endonasal administration in the treatment of diseases and disorders of the central nervous system
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc Method and composition for treating neurodegenerative disorders
AU2004212337A1 (en) * 2003-02-17 2004-08-26 Altana Pharma Ag Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders
US20060235056A1 (en) * 2003-04-29 2006-10-19 Olivier Bezencon Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives
CN1780663A (en) * 2003-04-30 2006-05-31 埃科特莱茵药品有限公司 9-azabicyclo nonylene derivatives with a heteroatom at the 3-position as renin inhibitors
BRPI0409818A (en) * 2003-04-30 2006-05-09 Actelion Pharmaceuticals Ltd compounds, pharmaceutical compositions, method for the treatment or prophylaxis of diseases, and uses of compounds and one or more compounds in combination with other pharmacologically active compounds
JP2006524657A (en) * 2003-04-30 2006-11-02 アクテリオン　ファマシューティカルズ　リミテッド New tropane derivative
US20060223795A1 (en) * 2003-05-02 2006-10-05 Oliver Bezencon Novel diazabicyclononene derivatives
US20050009789A1 (en) * 2003-05-13 2005-01-13 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Service Cyclooxygenase inhibition with nitroxyl
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
CA2536173A1 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2005023182A2 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US20050171207A1 (en) * 2003-09-26 2005-08-04 Myriad Genetics, Incorporated Method and composition for combination treatment of neurodegenerative disorders
CA2540543A1 (en) * 2003-10-09 2005-05-06 Actelion Pharmaceuticals Ltd Tetrahydropyridine derivatives
CN1867568A (en) * 2003-10-13 2006-11-22 埃科特莱茵药品有限公司 Diazabicyclononene derivatives and their use as renin inhibitors
AU2004283854A1 (en) * 2003-10-23 2005-05-06 Actelion Pharmaceuticals Ltd Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
US20070111989A1 (en) * 2003-12-05 2007-05-17 Olivier Bezencon Novel diazabicyclononene derivatives and use
AU2004295092A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd. Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
WO2005070006A2 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
WO2005084301A2 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
EP1778298A4 (en) * 2004-04-01 2010-03-31 Univ Pennsylvania Lipoprotein nanoplatforms
US20050252144A1 (en) * 2004-04-29 2005-11-17 Macdonald Robert A Veneers for walls, retaining walls and the like
US7326809B2 (en) * 2004-05-27 2008-02-05 Antibe Therapeutics Inc. Salts of 4- or 5-aminosalicylic acid
HUE028158T2 (en) 2004-07-07 2016-12-28 Biocon Ltd Synthesis of azo bonded immunoregulatory compounds
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (en) * 2004-08-11 2008-06-10 Myriad Genetics Inc pharmaceutical composition and method for treating neurodegenerative disorders
ATE462703T1 (en) * 2004-08-25 2010-04-15 Actelion Pharmaceuticals Ltd BICYCLONONE DERIVATIVES AS RENIN INHIBITORS
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
CA2576279A1 (en) * 2004-11-08 2006-05-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
EP1846380A4 (en) * 2005-01-21 2010-02-17 Nicox Sa Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
JP2008530226A (en) * 2005-02-16 2008-08-07 ニトロメッド インコーポレーティッド Organic nitric oxide donor salts, compositions, and methods of use of antimicrobial compounds
AU2006218766A1 (en) * 2005-02-28 2006-09-08 Nicox S.A. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
US20090215838A1 (en) * 2005-03-09 2009-08-27 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
US20090075956A1 (en) * 2005-04-07 2009-03-19 Nitromed, Inc. Genetic Risk Assessment in Heart Failure: Impact of the Genetic Variation of NOS3
US7926484B2 (en) * 2005-05-03 2011-04-19 Aeon Research And Technology, Inc. Interface accessory for use with an aerosol inhalation system
WO2006127591A2 (en) * 2005-05-23 2006-11-30 Nitromed, Inc. Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
KR100963455B1 (en) * 2005-05-27 2010-06-18 액테리온 파마슈티칼 리미티드 Novel piperidine carboxylic acid amide derivatives
EP1909779A1 (en) * 2005-06-23 2008-04-16 Johns Hopkins University Thiol-sensitive positive inotropes
EA200800360A1 (en) * 2005-07-22 2008-06-30 Мириад Дженетикс, Инк. FORMS WITH HIGH CONTENT OF DRUGS AND DOSED FORMS
WO2007016095A2 (en) * 2005-07-27 2007-02-08 Nitromed, Inc. Cyclooxygenase-2 selective inhibitor compounds comprising nitric oxide enhancing groups, compositions and methods of use
EP1915157A4 (en) * 2005-08-02 2010-09-01 Nicox Sa Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
AU2006299383A1 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. Methods for treating respiratory disorders
AU2006299382A1 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. The genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor Gly389Arg polymorphism
WO2007059311A2 (en) * 2005-11-16 2007-05-24 Nitromed, Inc. Furoxan compounds, compositions and methods of use
WO2007075541A2 (en) * 2005-12-20 2007-07-05 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
US20080293702A1 (en) * 2005-12-22 2008-11-27 Nitromed, Inc. Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use
AU2007210813A1 (en) 2006-02-02 2007-08-09 Actelion Pharmaceuticals Ltd Secondary amines as renin inhibitors
AR059886A1 (en) * 2006-03-08 2008-05-07 Actelion Pharmaceuticals Ltd DERIVATIVES OF AMIDAS AS INHIBITORS OF RENINA
US8361494B2 (en) * 2006-03-10 2013-01-29 The Trustees Of The University Of Pennsylvania Biomimetic iron-oxide-containing lipoprotein and related materials
US8067414B2 (en) * 2006-03-29 2011-11-29 Nicox S.A. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
JP2007275193A (en) * 2006-04-04 2007-10-25 Fujifilm Corp Optical probe and optical tomographic imaging equipment
CA2646266A1 (en) * 2006-04-10 2007-10-25 Nitromed, Inc. Assessment of heart failure risk using genetic assessment of g-protein beta-3 subunit polymorphism
CA2685356A1 (en) * 2006-04-28 2007-11-08 Joslin Diabetes Center, Inc. Reducing risk of type 2 diabetes (t2d)
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
WO2008020028A1 (en) 2006-08-16 2008-02-21 Action Medicines, S.L. 2,5 dihydroxybenzene compounds for the treatment of rosacea
WO2008101064A1 (en) * 2007-02-14 2008-08-21 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist
WO2009012425A2 (en) * 2007-07-19 2009-01-22 Logigal Therapeutics, Inc. Compositions including leukotriene antagonists and nsaids and methods of using the same
EA020853B1 (en) * 2008-05-05 2015-02-27 Мерк Кэнэда Инк. 3,4-substituted piperidine derivatives as renin inhibitors
CN102458451B (en) 2009-06-09 2016-10-05 普罗朗制药有限责任公司 Hemoglobin compositions
WO2011041870A1 (en) * 2009-10-07 2011-04-14 Nitrogenix Inc. Non-steroidal anti-inflammatory drugs coadministered with nitric oxide amino acid ester compounds as prophylaxis in hypertensive patients
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
EP2509942A2 (en) 2009-12-07 2012-10-17 Johns Hopkins University Bis-acylated hydroxylamine derivatives
CA2782110A1 (en) * 2009-12-07 2011-06-16 Johns Hopkins University N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives
IL282010B (en) 2013-12-24 2022-07-01 Univ Virginia Commonwealth Uses of oxygenated cholesterol sulfates

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US242651A (en) * 1881-06-07 Electric cable and conductor
US4044125A (en) * 1975-07-18 1977-08-23 Eli Lilly And Company Method of stabilizing acetylsalicylic acid in the presence of d-propoxyphene hydrochloride and compositions thereof
CA1163561A (en) * 1979-11-06 1984-03-13 Cyril Boroda Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4547371A (en) * 1983-04-18 1985-10-15 Merck & Co., Inc. Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents
US4556672A (en) * 1984-03-19 1985-12-03 Pfizer Inc. 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US5081118A (en) * 1987-10-26 1992-01-14 Pfizer Inc. Benzothiazine dioxide derivatives
JPH0629271B2 (en) * 1988-03-09 1994-04-20 株式会社日本ハイポックス Benzothiazine-1,1-dioxide derivative and pharmaceutical composition containing the same
US5025001A (en) * 1988-06-15 1991-06-18 Brigham And Women's Hospital S-nitroso derivatives of ACE inhibitors and the use thereof
FR2650589A1 (en) * 1989-08-04 1991-02-08 Esteve Labor Dr BENZOTHIAZINIC DERIVATIVES, PREPARATION THEREOF AND THEIR APPLICATIONS AS MEDICAMENTS OR AS INTERMEDIATES OF SYNTHESIS OF DRUGS
US5570683A (en) 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
DK1023905T3 (en) * 1991-11-14 2005-05-30 Brigham & Womens Hospital Pharmaceutical preparation containing S-nitroso immunoglobulins and use thereof
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
AT399880B (en) * 1992-07-03 1995-08-25 Chem Pharm Forsch Gmbh NEW THIENOTHIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
DE69308563T2 (en) * 1992-07-17 1997-06-12 Dow Chemical Co METHOD FOR PRODUCING BORCARBIDE ALUMINUM CERMETS, WITH CONTROLLED STRUCTURE
GB2284350B (en) * 1992-07-30 1996-08-28 Cal Int Ltd Pharmaceutical compositions comprising esters of organic nitrates and a salicylate
IT1256345B (en) * 1992-08-20 1995-12-01 NITRIC ESTERS OF PHENYLACETIC 2- (2,6-DI-HALO-PHENYLAMIN) DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
IT1256450B (en) * 1992-11-26 1995-12-05 Soldato Piero Del NITRIC ESTERS WITH PHARMACOLOGICAL ACTIVITY AND PROCEDURE FOR THEIR PREPARATION
US5344929A (en) * 1993-02-18 1994-09-06 Alcon Laboratories, Inc. Preparation of carbonic anhydrase inhibitors
US5840701A (en) * 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
EP1393723A3 (en) * 1993-09-17 2004-10-20 The Brigham And Women's Hospital, Inc. Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces
DK0722434T3 (en) * 1993-10-06 1998-11-16 Nicox Sa Nitric acid esters having anti-inflammatory and / or analgesic activity and methods for their preparation
EP0658559A1 (en) * 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazin derivatives, process for their preparation and their use as 5-dipoxygenase and cyclooxygenase inhibitors
US5538966A (en) * 1994-01-21 1996-07-23 Alcon Laboratories, Inc. Carbonic anhydrase inhibitors
HU227280B1 (en) * 1994-05-10 2011-01-28 Nicox Sa Nitro compounds and their compositions having anti-inflammatory, analgesic and antithrombotic acitivities
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US6051588A (en) * 1995-04-19 2000-04-18 Nitromed Inc Nitroso esters of β-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US6043232A (en) 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US5620416A (en) * 1995-06-07 1997-04-15 North Carolina State University Methods of using topical agents with systemically administered active agents
IT1276071B1 (en) * 1995-10-31 1997-10-24 Nicox Ltd ANTI-INFLAMMATORY ACTIVITY COMPOSITES
IT1282686B1 (en) * 1996-02-26 1998-03-31 Nicox Sa COMPOUNDS ABLE TO REDUCE DRUG TOXICITY
IT1288123B1 (en) * 1996-09-04 1998-09-10 Nicox Sa USE OF NITRO-DERIVATIVES FOR URINARY INCONTINENCE

Also Published As

Publication number Publication date
US6790864B2 (en) 2004-09-14
JPH11509519A (en) 1999-08-24
EP0821589A1 (en) 1998-02-04
US20050038029A1 (en) 2005-02-17
US6048858A (en) 2000-04-11
US5703073A (en) 1997-12-30
US6482846B1 (en) 2002-11-19
US20080275010A1 (en) 2008-11-06
US20030109520A1 (en) 2003-06-12
US6057347A (en) 2000-05-02
CA2218555C (en) 2003-09-23
US6323234B1 (en) 2001-11-27
AU710951B2 (en) 1999-09-30
WO1996032946A1 (en) 1996-10-24
EP0821589A4 (en) 2002-05-15
US6083515A (en) 2000-07-04
US20060276439A1 (en) 2006-12-07
EP0821589B1 (en) 2009-02-04
JP2007291127A (en) 2007-11-08
AU5449396A (en) 1996-11-07
US6043233A (en) 2000-03-28

Similar Documents

Publication Publication Date Title
CA2218555A1 (en) Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
CA2140106A1 (en) Method of treating hyperproliferative vascular disease
CA2239174A1 (en) Novel compounds with analgesic effect
AU6194894A (en) Bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
CA2274074A1 (en) Novel compounds with analgesic effect
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
DE69826684D1 (en) COVALENT-TIED N, O-CARBOXYMETHYLCHITOSAN AND ITS USE
AU5647199A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
AU3176695A (en) Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid
AU4702093A (en) More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
CA2116829A1 (en) Use of a pregnane derivative
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
ID17875A (en) PHARMACEUTICAL COMPOSITION THAT CONTAINS 4-OXSOBUTANOIC ACID
AU5443499A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
AU2187197A (en) Transdermally administered acetylcysteine as mucolytic agent
CA2362833A1 (en) Phenylalaninol derivatives
AU3189197A (en) Agricultural compositions containing glycolic acid
EP0978287A4 (en) MEDICINAL COMPOSITION CONTAINING gp34 BINDING INHIBITOR AS THE ACTIVE INGREDIENT
ZA975755B (en) Useful formulations of acid addition salt drugs.
CA2192481A1 (en) Drug salts
IT1271417B (en) COMPOUNDS WITH ANTIHISTAMIN ACTIVITY PROCEDURE FOR THEIR PREPERATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
WO1997026968A3 (en) Therapeutic anti-asthma agents containing selenium compounds
AU1101301A (en) 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
AU5251493A (en) Oxalyl hydrazide-hydroxamic acid derivatives, their preparation and their use as fungicides

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed